Head-to-head evidence
BCMA CAR-NK (Shenzhen Pregene Biopharma) vs Trovocabtagene autoleucel (C-CAR088)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
BCMA CAR-NK (Shenzhen Pregene Biopharma)
Developed by Shenzhen Pregene Biopharma Co., Ltd.
NCT05652530 · Phase 1 · status unknown
This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.
Trovocabtagene autoleucel (C-CAR088)
Developed by AbelZeta Pharma, Inc.
NCT03751293 · Phase 1 · status unknown
This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape